Skip to main content

Table 1 Patient characteristics at initiation of gemcitabine and nab-paclitaxel

From: Gemcitabine plus nab-paclitaxel for advanced pancreatic cancer after first-line FOLFIRINOX: single institution retrospective review of efficacy and toxicity

Age, years 61 (50–74)
Sex, no (%)
 Male 11 (39.3 %)
 Female 17 (60.7 %)
Disease, no (%)
 Metastatic 23 (82.1 %)
 Locally advanced 5 (17.9 %)
ECOG performance status, no (%)
 ≤1 27 (96.4 %)
 ≥2 1 (3.6 %)
Median no of FOLFIRINOX cycles (range) 12 (5–46)
Median interval from last FOLFRINOX to initiation of G + Nab-P, weeks (range) 5.4 (1.7–40.3)
N = 28